Filters

Term Search
You can select from the dropdown list OR enter your own terms to refine the search.

Last Updated: 10/31/2025

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 66 publications

Targeted Therapy in HER2 Exon 20-Mutant Non-small Cell Lung Cancer With Leptomeningeal Disease: A Case-Based Approach to Treatment Decision-Making.

Targeted Therapy in HER2 Exon 20-Mutant Non-small Cell Lung Cancer With Leptomeningeal Disease: A Case-Based Approach to Treatment Decision-Making.

Journal: Cureus
Published: July 28, 2025

Stabilization of Symptomatic Bone Marrow Metastases in Breast Cancer: A Case Report of Two Patients Treated With Trastuzumab Deruxtecan.

Stabilization of Symptomatic Bone Marrow Metastases in Breast Cancer: A Case Report of Two Patients Treated With Trastuzumab Deruxtecan.

Journal: Cureus
Published: July 01, 2025

Antibody-Drug Conjugates Powered by Deruxtecan: Innovations and Challenges in Oncology.

Antibody-Drug Conjugates Powered by Deruxtecan: Innovations and Challenges in Oncology.

Journal: International journal of molecular sciences
Published: June 11, 2025

Complete response to trastuzumab-deruxtecan (Enhertu, T-DXd) in HER2-positive stage IVB uterine carcinosarcoma.

Complete response to trastuzumab-deruxtecan (Enhertu, T-DXd) in HER2-positive stage IVB uterine carcinosarcoma.

Journal: Gynecologic oncology reports
Published: May 10, 2025

Elucidating Critical Factors of Internalization and Drug Release of Antibody-Drug Conjugates (ADCs) Using Kinetic Parameters Evaluated by a Novel Tool Named TORCH.

Elucidating Critical Factors of Internalization and Drug Release of Antibody-Drug Conjugates (ADCs) Using Kinetic Parameters Evaluated by a Novel Tool Named TORCH.

Journal: Bioconjugate chemistry
Published: May 06, 2025

Long Durable Response With Trastuzumab Deruxtecan Monotherapy in a Triple-Negative Metastatic Breast Cancer Patient With Human Epidermal Growth Factor Receptor 2 Mutation: A Long-Term Follow-Up and Literature Review.

Long Durable Response With Trastuzumab Deruxtecan Monotherapy in a Triple-Negative Metastatic Breast Cancer Patient With Human Epidermal Growth Factor Receptor 2 Mutation: A Long-Term Follow-Up and Literature Review.

Journal: Journal of medical cases
Published: April 29, 2025

HER2 mutation profiling in mucinous ovarian carcinoma: Inferences for Enhertu (trastuzumab deruxtecan) as a potential therapeutic approach.

HER2 mutation profiling in mucinous ovarian carcinoma: Inferences for Enhertu (trastuzumab deruxtecan) as a potential therapeutic approach.

Journal: Taiwanese journal of obstetrics & gynecology
Published: April 24, 2025

Advanced Antibody-Drug Conjugates Design: Innovation in Linker Chemistry and Site-Specific Conjugation Technologies.

Advanced Antibody-Drug Conjugates Design: Innovation in Linker Chemistry and Site-Specific Conjugation Technologies.

Journal: Chembiochem : a European journal of chemical biology
Published: April 11, 2025

Comparative pharmacological analysis of fam-trastuzumab deruxtecan-nxki and sacituzumab govitecan-hziy: Two recently developed chemotherapies in the crucial battle against breast cancer.

Comparative pharmacological analysis of fam-trastuzumab deruxtecan-nxki and sacituzumab govitecan-hziy: Two recently developed chemotherapies in the crucial battle against breast cancer.

Journal: Toxicology reports
Published: March 06, 2025

Camptothein-Based Anti-Cancer Therapies and Strategies to Improve Their Therapeutic Index.

Camptothein-Based Anti-Cancer Therapies and Strategies to Improve Their Therapeutic Index.

Journal: Cancers
Published: February 06, 2025

Patterns of HER2 expression and genomic correlates in lung cancer, with a focus on preanalytical variables impacting immunohistochemical staining results.

Patterns of HER2 expression and genomic correlates in lung cancer, with a focus on preanalytical variables impacting immunohistochemical staining results.

Journal: Journal of clinical pathology
Published: February 03, 2025

A novel DNA sequence-selective, guanine mono-alkylating ADC payload suitable for solid tumour treatment.

A novel DNA sequence-selective, guanine mono-alkylating ADC payload suitable for solid tumour treatment.

Journal: RSC medicinal chemistry
Published: December 27, 2024
Showing 1-12 of 66

Last Updated: 10/31/2025